In the past 5 years, the FDA has awarded 4 drugs 9 new indications for the treatment of advanced ovarian cancers. Although these approvals represent a welcome expansion of the therapeutic toolkit for this challenging malignancy, the arrival of new options has outpaced efforts to discover the best use for each medication.
Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.
Camille C. Gunderson, MD, discusses the various maintenance options available in advanced ovarian cancer, as well as what factors should be considered for selecting each approach.
Debra Richardson, MD, FACOG, FACS, discusses the current indications for PARP inhibitors in the recurrent setting and ongoing work being done to broaden their utility in the field.
Linda R. Duska, MD, discusses the ongoing debate between upfront surgery and neoadjuvant chemotherapy in ovarian cancer and the data that support both options.
Kathleen Moore, MD, combs through the various investigational strategies exploring management of resistance to PARP inhibitors in ovarian cancer.
Laura L. Holman, MD, discusses ongoing efforts in ovarian cancer screening and what may lie ahead for generations to come.
Alexander Olawaiye, MD, discusses the trials that led to the expanded approvals of PARP inhibitors as maintenance therapy in women with platinum-sensitive ovarian cancer.
Jessica L. Berger, MD, evaluates the treatment approaches available for patients with newly diagnosed advanced ovarian cancer.
At the 2019 OncLive® State of the Science Summit™ on Ovarian Cancer, we asked experts from the University of Pittsburgh Medical Center about the intriguing research being conducted at their institution.